Abstract:Background: IκBζ, a rather unknown co-regulator of NF-κB, is mostly inducibly expressed and can either activate or repress a specific subset of NF-κB target genes. While its role as a transcriptional regulator of various cytokines and chemokines in immune cells has been revealed, the function of IκBζ in solid cancer remains unclear. Methods: We investigated IκBζ expression in melanoma, and assessed its impact on target gene expression, tumor growth, and response to immunotherapy in melanoma cell lines, mouse models, and patient samples. Results: Unlike in other cell types, IκBζ protein was found to be constitutively expressed in a subfraction of melanoma cell lines, and around 35% of melanoma cases. This atypical expression pattern of IκBζ did not correlate with its mRNA levels or known driver mutations, but instead seemed to result from changes in its post-transcriptional or post-translational regulation. Deleting constitutively expressed IκBζ abrogated the activity and chromatin association of STAT3 and p65, leading to reduced expression of the pro-proliferative cytokines IL-1β and IL-6 in melanoma cells. Consequently, loss of tumor-derived IκBζ suppressed selfsustained melanoma cell growth both in vitro and in vivo. Additionally, constitutive IκBζ expression suppressed the induction of the chemokines CXCL9, CXCL10, and CCL5, which impaired the recruitment of NK and CD8+ T-cells to the tumor, causing resistance to α-PD-1 immunotherapy in mice. Furthermore, the expression of tumor-derived IκBζ also correlated with the absence of CD8+ T-cells in human melanoma samples and progressive disease during immunotherapy. Conclusion: We propose that tumor-derived IκBζ could serve as a new therapeutic target and prognostic marker that characterizes melanoma with high tumor cell proliferation, cytotoxic T- and NK-cell exclusion, and unfavorable immunotherapy responses. Targeting IκBζ expression might open up a new therapy option to re-establish the recruitment of cytotoxic cells, thereby resensitizing for immunotherapy.

MAPK and PI3K/AKT mediated YB-1 activation promotes melanoma cell proliferation which is counteracted by an autoregulatory loop

YB-1 Oncoprotein Controls PI3K/Akt Pathway by Reducing Pten Protein Level

Yap Promotes The Proliferation Of Neuroblastoma Cells Through Decreasing The Nuclear Location Of P27(Kip1) Mediated By Akt

Effect and Mechanism of YB-1 Knockdown on Glioma Cell Growth, Migration, and Apoptosis.

YB-1 is a Positive Regulator of KLF5 Transcription Factor in Basal-Like Breast Cancer

IGPR-1 is phosphorylated on the immunoreceptor tyrosine-based motif, stimulates AKT pathway and supports melanoma growth

Critical Role of Phosphorylation of Serine 165 of YBX1 on the Activation of NF-κB in Colon Cancer.

ΔNp63α controls YB-1 protein stability: evidence on YB-1 as a new player in keratinocyte differentiation

Oncogenic DNA methyltransferase 1 activates the PI3K/AKT/mTOR signalling by blocking the binding of HSPB8 and BAG3 in melanoma

Akt-Mediated Phosphorylation of Bmi1 Regulates Its Chromatin Association and Growth Promoting Properties.

IKBKE promotes glioblastoma progression by establishing the regulatory feedback loop of IKBKE/YAP1/miR-Let-7b/i.

Constitutive expression of IκBζ promotes tumor growth and immunotherapy resistance in melanoma

Oncogenic B-RafV600E Abrogates the AKT/B-Raf/Mps1 Interaction in Melanoma Cells

Effect of Y-box binding protein 1 on tumor and its research

Y-Box Protein 1 Stimulates Mesangial Cell Proliferation Via Activation of ERK1/2

PP2A-B56α controls oncogene-induced senescence in normal and tumor human melanocytic cells

Loss of YY1, a Regulator of Metabolism in Melanoma, Drives Melanoma Cell Invasiveness and Metastasis Formation

Upregulated YB-1 Protein Promotes Glioblastoma Growth Through a YB-1/CCT4/mLST8/mTOR Pathway

[Functions of Y-box Binding Protein and Its Role in Tumorigenicity].

Pp2a-B56 Alpha Controls Oncogene-Induced Senescence In Normal And Tumor Human Melanocytic Cells

YB-1 Regulates Tumor Growth by Promoting MACC1/c-Met Pathway in Human Lung Adenocarcinoma